Perspective | I’m in my early 20s. Why do I have breast cancer?
Cancer among young patients isn’t common, but it’s on the rise. For young patients like me, it’s hard to wrap our minds around the randomness of it all.
Cancer among young patients isn’t common, but it’s on the rise. For young patients like me, it’s hard to wrap our minds around the randomness of it all.
🌟 Join Our Team at Fox Chase – Temple Urologic Institute 🌟 Position: PHYSICIAN ASSISTANT (FT; 40hrs/wk) – Urology / Urologic Oncology at Jeanes Hospital…
8,428 likes, 434 comments – vinicius_kaiser on May 7, 2024: “Reclama agora do Exército!! 😂♥️”.
Anaplastic large cell lymphoma (ALCL) is an uncommon type of non-Hodgkin’s lymphoma (NHL), as well as one of the subtypes of T cell lymphoma, accounting…
AbstractBackground:. Sapanisertib (CB-228/TAK-228) is a potent, selective ATP-competitive, dual inhibitor of mTORC1/2. Metformin is thought to inhibit the mTOR pathway through upstream activation of 5′-AMP-activated…
Novel tissue-agnostic therapeutics targeting driver mutations in tumor cells have been recently approved by FDA, driven by basket trials that have demonstrated their efficacy and…
PURPOSE Human epidermal growth factor receptor 2 (HER2) is an effective therapeutic target in breast and gastric and gastroesophageal junction cancers. However, less is known…
PURPOSE To study whether BRAF V600 mutations in non–small-cell lung cancer (NSCLC) may indicate sensitivity to the BRAF inhibitor vemurafenib, we included a cohort of…
Purpose Parallel activation of the phosphatidylinositol 3-kinase–mammalian target of rapamycin pathway represents a mechanism of primary and acquired resistance to BRAF-targeted therapy, but the two…
One to two percent of non–small-cell lung cancers (NSCLCs) harbor ROS1 gene rearrangements. 1 – 3 ROS1 gene rearrangement leads to constitutive activation receptor tyrosine…